Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.13|
|52 Week High||AU$0.13|
|52 Week Low||AU$0.29|
|1 Month Change||-10.71%|
|3 Month Change||n/a|
|1 Year Change||-52.83%|
|3 Year Change||-53.70%|
|5 Year Change||-63.24%|
|Change since IPO||-98.75%|
Recent News & Updates
We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, Immuron ( ASX:IMC...
|IMC||AU Biotechs||AU Market|
Return vs Industry: IMC underperformed the Australian Biotechs industry which returned 3.7% over the past year.
Return vs Market: IMC underperformed the Australian Market which returned 24.4% over the past year.
Stable Share Price: Insufficient data to determine IMC's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine IMC's volatility change over the past year.
About the Company
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver.
Immuron Fundamentals Summary
|IMC fundamental statistics|
Is IMC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMC income statement (TTM)|
|Cost of Revenue||AU$810.84k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.037|
|Net Profit Margin||-5,751.61%|
How did IMC perform over the long term?See historical performance and comparison
Is Immuron undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IMC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IMC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IMC is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: IMC is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMC is good value based on its PB Ratio (1.1x) compared to the AU Biotechs industry average (4.9x).
How is Immuron forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immuron has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Immuron performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMC is currently unprofitable.
Growing Profit Margin: IMC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMC is unprofitable, but has reduced losses over the past 5 years at a rate of 1.1% per year.
Accelerating Growth: Unable to compare IMC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (48%).
Return on Equity
High ROE: IMC has a negative Return on Equity (-32.38%), as it is currently unprofitable.
How is Immuron's financial position?
Financial Position Analysis
Short Term Liabilities: IMC's short term assets (A$25.8M) exceed its short term liabilities (A$1.1M).
Long Term Liabilities: IMC's short term assets (A$25.8M) exceed its long term liabilities (A$36.2K).
Debt to Equity History and Analysis
Debt Level: IMC is debt free.
Reducing Debt: IMC has no debt compared to 5 years ago when its debt to equity ratio was 38.3%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: IMC has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 8.9% each year
What is Immuron current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jerry Kanellos (60 yo)
Dr. Jerry Kanellos, Ph D has been Chief Executive Officer of Immuron Limited since March 25, 2020 and is its Chief Operating Officer since July 2015. Dr. Kanellos served as Interim Chief Executive Officer...
CEO Compensation Analysis
Compensation vs Market: Jerry's total compensation ($USD183.31K) is below average for companies of similar size in the Australian market ($USD301.38K).
Compensation vs Earnings: Jerry's compensation has been consistent with company performance over the past year.
Experienced Board: IMC's board of directors are considered experienced (8.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Immuron Limited's employee growth, exchange listings and data sources
- Name: Immuron Limited
- Ticker: IMC
- Exchange: ASX
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$28.406m
- Shares outstanding: 227.25m
- Website: https://www.immuron.com.au
- Immuron Limited
- 25-37 Chapman Street
- Unit 10
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 07:02|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.